Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.
Cancer Res. 2021 May 1;81(9):2259-2269. doi: 10.1158/0008-5472.CAN-20-2978. Epub 2021 Jan 28.
CUB-domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein that is upregulated in malignancies of the breast, lung, colorectum, ovary, kidney, liver, pancreas, and hematopoietic system. Here, we discuss CDCP1 as an important hub for oncogenic signaling and its key roles in malignant transformation and summarize approaches focused on exploiting it for cancer diagnosis and therapy. Elevated levels of CDCP1 are associated with progressive disease and markedly poorer survival. Predominantly located on the cell surface, CDCP1 lies at the nexus of key tumorigenic and metastatic signaling cascades, including the SRC/PKCδ, PI3K/AKT, WNT, and RAS/ERK axes, the oxidative pentose phosphate pathway, and fatty acid oxidation, making important functional contributions to cancer cell survival and growth, metastasis, and treatment resistance. These findings have stimulated the development of agents that target CDCP1 for detection and treatment of a range of cancers, and results from preclinical models suggest that these approaches could be efficacious and have manageable toxicity profiles.
CUB 结构域包含蛋白 1(CDCP1)是一种 I 型跨膜糖蛋白,在乳腺癌、肺癌、结直肠癌、卵巢癌、肾癌、肝癌、胰腺癌和造血系统恶性肿瘤中上调。在这里,我们将 CDCP1 作为致癌信号的重要枢纽,并讨论其在恶性转化中的关键作用,并总结了针对利用它进行癌症诊断和治疗的方法。CDCP1 水平升高与疾病进展和明显较差的生存相关。CDCP1 主要位于细胞表面,位于关键的致癌和转移信号级联的交点,包括 SRC/PKCδ、PI3K/AKT、WNT 和 RAS/ERK 轴、氧化戊糖磷酸途径和脂肪酸氧化,对癌细胞的存活和生长、转移和治疗耐药性做出重要的功能贡献。这些发现刺激了针对 CDCP1 的检测和治疗一系列癌症的药物的开发,临床前模型的结果表明,这些方法可能有效,且具有可管理的毒性特征。